Mr. Delaney began his role as Aadi’s President and CEO on January 1, 2023, having previously served as the Company’s Chief Operating Officer from September 2021. Before Aadi, Mr. Delaney served as the Chief Commercial Officer (CCO) of Constellation Pharma which was acquired by MorphoSys for $1.7 billion. Prior to joining Constellation, Mr. Delaney was the CCO at Immunomedics, where he led the buildout of the marketing, sales, market access, and commercial operations teams. He was instrumental in successfully launching Trodelvy, the first TROP-2 directed antibody-drug conjugate for the treatment of triple-negative breast cancer. Immunomedics was acquired by Gilead Sciences for $21 billion in September 2020. Previously, he served as the head of U.S. hematology and oncology at Celgene Corporation, where he managed a portfolio of brands including Revlimid, Pomalyst and Abraxane. Prior to joining Celgene, he held various commercial roles at both Novartis Oncology and Genentech, where he led several successful product launches for blockbuster brands. He earned an MBA from the Stern School of Business at NYU and a BS in biology from Rutgers University.
Dr. Itri joined Aadi in October 2021 as the Chief Medical Officer. She was most recently the CMO at Immunomedics, and before that, Executive Vice President of Global Health Sciences & Regulatory Affairs at The Medicines Company. Previously, she was president of Pharmaceutical Development and CMO at Genta, Inc. Prior to that, Dr. Itri served as Senior Vice President of Medical and Regulatory Affairs at Johnson & Johnson’s Pharmaceutical Research Institute. In addition, she served as SVP of Clinical Affairs and CMO for Ortho Biotech Inc., previously having served as Assistant Vice President of Clinical Development in immunology and oncology at Hoffmann-La Roche. Dr. Itri began her career at Hoffmann-La Roche as Assistant Vice President of Clinical Development in immunology and oncology. Dr. Itri received her MD from New York Medical College, completed her medical residency at SUNY-Stony Brook, and her fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center where she was an adjunct attending physician for more than 15 years. Dr. Itri has served as a member of the National Cancer Institute Board of Scientific Counselors and has published extensively on the development of therapeutic agents.
Mr. Giacobello currently serves as Aadi’s Chief Financial Officer, joining the Company in November 2021. He had previously served as the CFO for GW Pharmaceuticals, playing a key role in the buildout of U.S. operations and commercial readiness for the launch of their lead product, EPIDIOLEX®, which had sales of over $296 million in its first full year of commercialization. Mr. Giacobello led the company’s financing strategy, raising more than $620 million to support this development, approval, and product launch leading up to their eventual acquisition by Jazz Pharmaceuticals in 2021. Mr. Giacobello had previously served as CFO of Chase Pharmaceuticals Corporation prior to its acquisition by Allergan plc, where he held senior level finance roles including Vice President of Finance, Global Research and Development.
Mr. Rodin joined Aadi in February 2022 as SVP and General Counsel. He was most recently the Executive Vice President and General Counsel of The Medicines Company, which was acquired by Novartis for $9.7B in January 2020. During his 13-year tenure at The Medicines Company, Steve led or played a substantial role in $750M+ of acquisitions and $650M+ of divestitures. Prior to that, Steve was a corporate attorney at Proskauer Rose LLP in New York. He earned a JD from Vanderbilt University Law School, where he currently sits on the Board of Advisors, and an AB from Georgetown University.
Mr. Ball serves as Aadi’s Chief Quality Officer and SVP Manufacturing Operations, bringing 25 years of experience leading quality, manufacturing and supply chain teams in healthcare regulated industries. Most recently, Mr. Ball served as the CQO and SVP Operations at Intercept Pharmaceuticals, where he oversaw commercial product and prepared the organization to support regulatory submission of pipeline candidates. Prior to Intercept, Mr. Ball served as CQO at Immunomedics, acquired by Gilead Sciences, where he joined after serving as SVP, Global Quality and Safety, Health, and Environmental for Mallinckrodt Pharmaceuticals. Mr. Ball holds an MBA from Westminster College, a Master of Science in Biology from the University of North Carolina and a BS in Biology from Central Michigan University.
Mr. Steitz joined Aadi in June 2022 as the Senior Vice President & Chief Human Resources Officer, most recently having served as the SVP of Human Resources at Vyne Therapeutics where he partnered with senior leadership and led the build out of the corporate and commercial groups to support the company’s strategic growth plans. Prior to joining Vyne, Mr. Steitz was SVP of Human Resources for Olam Americas and previously Vice President of Human Resources for Warner Chilcott. Prior to these senior leadership roles, he held various Human Resources roles of increasing responsibility at Unilever and Philips N.V. Mr. Steitz earned a BS Degree in Business from Rider University.
Ms. Graham currently serves as Aadi’s Senior Vice President of Investor Relations and Corporate Communications, joining the Company in May 2022. She brings more than 20 years of experience to the role, having led these functional areas primarily at biotech and pharmaceutical companies in all stages of development. Ms. Graham most recently served as the Vice President of Corporate Affairs at Poseida Therapeutics, taking the company public in 2020 after joining in 2018. Prior to that role, Ms. Graham was Vice President IR and Corporate Communications at Mirati Therapeutics and had previously led investor relations and corporate communications for Ambit Biosciences prior to its eventual acquisition by Daiichi Sankyo in 2014. Other roles include similar functions with diagnostics companies Sequenom and Genoptix, the latter of which was acquired by Novartis in 2011. Ms. Graham earned an MBA from the University of New Mexico, Anderson School of Management and a BA in journalism, most recently completing the Strategic Financial Leadership Program at Stanford Graduate School of Business.
Mr. Kwon brings 13 years of biotech industry experience focused on business development and commercial strategy in oncology and has spent 11 years as a strategy consultant working with top biopharma companies. He was originally trained as a cancer biologist and has held positions as a Research Scientist at Memorial Sloan Kettering Cancer Center and an Associate at Radius Ventures. Andrew received a BS in Biology from Brown University, PhD in Molecular and Medical Pharmacology from University of California Los Angeles, and MBA from Columbia Business School.